Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

Cancer Research

Volumn 65, Issue 3, 2005, Pages 1089-1096

  Hirano, Fumiya ^a   Kaneko, Katsumi ^a   Tamura, Hideto ^a   Dong, Haidong ^a   Wang, Shengdian ^a,b   Ichikawa, Masao ^a,b   Rietz, Cecilia ^a,b   Flies, Dallas B ^a,b   Lau, Julie S ^a   Zhu, Gefeng ^a,b   Tamada, Koji ^a,b   Chen, Lieping ^a,b,c  

^a MAYO GRADUATE SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; B7 H1 ANTIGEN; CD137 MONOCLONAL ANTIBODY; CD8 ANTIGEN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10B5; MONOCLONAL ANTIBODY 2A; MONOCLONAL ANTIBODY G4; PROGRAMMED DEATH 1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD80; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CLONAL ANERGY; FEMALE; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 13444270323     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature 2001;411:380-4.
2. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38.
3. Prevost-Blondel A, Zimmermann C, Stemmer C, et al. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 1998;161:2187-94.
4. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188;1641-50.
5. Benlalam H, Labarriere N, Linnard B, et al. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL) implications for immunotherapy. Eur J Immunol 2002;31:2007-15.
6. Nelson DJ, Mukherjee S, Bundell C, et al. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J Immunol 2001;166:5557-66.
7. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97-113.
8. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-9.
9. Wang S, Bajorath J, Flies DB, et al. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med 2003;197:1083-91.
10. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
11. Tamura H, Dong H, Zhu G, et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 2001;97:1809-16.
12. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
13. Petroff MG, Chen L, Philips TA, Hunt JS. B7 family molecules: novel immunomodulators at the maternalfetal interface. Placenta 2002;23:s95-101.
14. Selenko-Gebauer N, Majdic O, Szekeres A, et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 2003;170:3637-44.
15. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003;170;1257-66.
16. Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T-cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003;111:363-70.
17. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-47.
18. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
19. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319-22.
20. Ansari MJI, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003;198:63-9.
21. Salama A, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003;198:71-8.
22. Tseng SY, Otsuji M, Gorsk K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001;193:839-46.
23. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2002;2:261-8.
24. Shin T, Kennedy G, Gorski K, et al. Cooperative B7-1/2 (CD80/CD86) and B7-DC (PD-L2) costimulation of CD4 T cells independent of the PD-1 receptor. J Exp Med 2003;198:31-8.
25. Liu X, Gao JX, Wen J, et al. B7-DC/PD-L2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003;197:1721-30.
26. Kanai T, Totsuka T, Uraushihara K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol 2003;171:4156-63.
27. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003;63:6501-5.
28. Wintterle S, Schreiner B, Schneider D, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003;63:7462-7.
29. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
30. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of co-stimulation by B7 on T-cell mediated tumor immunity. J Exp Med 1994;179:523-32.
31. Melero I, Bach N, Hellström KE, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the costimulatory 4-1BB ligand: synergy with the CD28 costimulatory pathway. Eur J Immunol 1998;28:1116-21.
32. Yang G, Hellström KE, Mizuno M, Chen L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining interleukin-10 with B7-CD28 costimulation. J Immunol 1995;155:3897-903.
33. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD 137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002;109:651-9.
34. Chen L, Ashe S, Brady W, et al. Costimulation of antitumor immunity by the B7 counterreceptor for T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
35. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5.
36. Dong H, Zhu G, Tamada K, et al. B7-H1 determines accumulation and deletion of intrahepatic CD8+ T lymphocytes. Immunity 2004;20:327-36.
37. Chemnitz JM, Parry RV Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004;173:945-54.